Drexel University’s College of Medicine and Hahnemann Hospital are recruiting for a phase two clinical trial of Prochymal, a stem cell therapy developed by Osiris Therapeutics, Inc. The therapy is designed to treat patients with recent heart attacks to minimize scar formation and promote cardiac function by infusing patients with stem cells capable of differentiating into heart muscle cells.
